Antiprotease therapy in cancer: hot or not?

Bibliography

• DE LA CHAPELLE A: Genetic predisposition to colorectal cancer. Nat. Rev. Cancer (2004) 4:769-780.
   PubMed Web of Science ®Google Scholar
• NAROD SA, FOULKES WD: BRCA1 and BRCA2 1994 and beyond. Nat. Rev. Cancer (2004) 4:665-676.
   PubMed Web of Science ®Google Scholar
• SIEBER OM, HAINIMAN K, TOMLINSON PM: Genomic instability – the engine of tumourigenesis. Nat. Rev. Cancer (2003) 3:701-708.
   PubMed Web of Science ®Google Scholar
• MICHALOGLOU C, VREDEVELD LC, SOENGAS MS et al.: BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature (2005) 436:720-724.
   PubMed Web of Science ®Google Scholar
• GOTTESMAN MM, FOJO T, BATES UL: Multidrug resistence in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer (2001) 2:48-56.
   Web of Science ®Google Scholar
• THIERY JP: Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer (2002) 2:442-454.
   PubMed Web of Science ®Google Scholar
• FRIEDL P, WOLF K: Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer (2003) 3:362-374.
   PubMed Web of Science ®Google Scholar
• BERGERS G, BENJAMIN LE: Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer (2003) 3:401-410.
   PubMed Web of Science ®Google Scholar
• STEEG PS: Metastasis suppressors alter the signal transduction of cancer cells. Nat. Rev. Cancer (2003) 3:55-63.
   PubMed Web of Science ®Google Scholar
• PANTEL K, BRAKENHOFF RH: Dissecting the metastatic cascade. Nat. Rev. Cancer (2004) 4:448-456.
   PubMed Web of Science ®Google Scholar
• TARIN D: The fallacy of epithelial mesenchymal transition in neoplasia. Cancer Res. (2005) 65:5996-6001.
   PubMed Web of Science ®Google Scholar
• FOLKMAN J: Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical application of research on angiogenesis. N. Engl. J. Med. (1995) 333:1757-1763.
   PubMed Web of Science ®Google Scholar
• NERI D, BICKNELL R: Tumour vascular targeting. Nat. Rev. Cancer (2005) 5:436-446.
   PubMed Web of Science ®Google Scholar
• YU JL, COOMBER BL, KERBEL RS: A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. Differentiation (2002) 70:599-609.
   PubMed Web of Science ®Google Scholar
• JANSEN M, DE WITT HAMER PC, WITMER AN, TROOST D, VAN NOORDEN CJ: Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas. Brain Res. Rev. (2004) 45:143-163.
   PubMed Web of Science ®Google Scholar
• BARRETT AJ, RAWLINGS ND, WOESSNER JF: The Handbook of Proteolytic Enzymes. 2nd ed. Barrett AJ, Rawlings ND, Woessner JF (Eds), Academic Press, Cambridge, UK (2004).
   Google Scholar
• PUENTE XS, SANCHEZ LM, OVEERALL CM, LÓPEZ-OTÍN C: Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. (2003) 4:544-588.
   PubMed Web of Science ®Google Scholar
• ROOSE JP, VAN NOORDEN CJ: Synthetic protease inhibitors: promising compounds to arrest pathobiologic processes. J. Lab. Clin. Med. (1995) 125:433-441.
   PubMedGoogle Scholar
• MATRISIAN LM, SLEDGE GW JR, MOHLA S: Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res. (2003) 63:6105-6109.
   PubMedGoogle Scholar
• KATUNUMA N, TSUGE H, NUKATSUKA M, ASAO T, FUKUSHIMA M: Structure-based design of specific cathepsin inhibitors and their application to protection of bone metastases of cancer cells. Arch. Biochem. Biophys. (2002) 397:305-311.
   PubMed Web of Science ®Google Scholar
• NEIDLE S, THURSTON DE: Chemical approaches to the discovery and development of cancer therapies. Nat. Rev. Cancer (2005) 5:285-296.
   PubMed Web of Science ®Google Scholar
• ZUCKER S, CAO J, CHEN WT: Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene (2000) 19:6642-6650.
   PubMed Web of Science ®Google Scholar
• COUSSENS LM, FINGLETON B, MATRISIAN LM: Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science (2002) 295:2387-2392.
   PubMed Web of Science ®Google Scholar
• VIHINEN P, ALA-AHO R, KAHARI VM: Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Targets (2005) 5:203-220.
   PubMed Web of Science ®Google Scholar
• EL-ANEED A: An overview of current delivery systems in cancer gene therapy. J. Control. Release (2004) 94:1-14.
   PubMed Web of Science ®Google Scholar
• SCHMITT M, JAENICKE F, GRAEFF H: Tumor-associated proteases. Fibrinol. Proteol. (1992) 6:3-26.
   Google Scholar
• CAVALLO-MEDVED D, SLOANE BF: Cell surface cathepsin B: understanding its functional signifiance. Curr. Top. Dev. Biol. (2003) 54:313-341.
   PubMed Web of Science ®Google Scholar
• SABEH F, OTA I, HOLMBECK K et al.: Tumor cell traffic through the extracellular matrix is controlled by the membrane-anchored collagenase MT1-MMP. J. Cell Biol. (2004) 167:769-781.
   PubMed Web of Science ®Google Scholar
• JESSANI N, LIU Y, HUMPHREY M, CRAVATT BF: Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA (2002) 99:10335-10340.
   PubMed Web of Science ®Google Scholar
• LEVIČAR N, NUTTALL RK, LAH TT: Proteases in brain tumour progression. Acta Neurochir. (Wien) (2003) 145:825-838.
   PubMed Web of Science ®Google Scholar
• LYNCH CC, MATRISIAN LM: Matrix metalloproteinases in tumor-host cell communication. Differentiation (2002) 70:561-573.
   PubMed Web of Science ®Google Scholar
• DE BOCK CE, WANG Y: Clinical significance of urokinase-type plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. (2004) 24:13-39.
   PubMed Web of Science ®Google Scholar
• TURK B, TURK D, SALVESEN GS: Regulating cysteine protease activity: essential role of protease inhibitors as guardians and regulators. Curr. Pharm. Des. (2002) 8:1623-1637.
   PubMed Web of Science ®Google Scholar
• SMORENBURG SM, GRIFFINI P, TIGGELMAN AM, MOORMAN AF, BOERS W, VAN NOORDEN CJ: Alpha2-macroglobulin is mainly produced by cancer cells and not by hepatocytes in rats with colon carcinoma metastases in liver. Hepatology (1996) 23:560-570.
   PubMed Web of Science ®Google Scholar
• GRIFFINI P, SMORENBURG SM, VOGELS IM, TIGCHELAAR W, VAN NOORDEN CJ: Kupffer cells and pit cells are not effective in the defense against experimentally induced colon carcinoma metastasis in rat liver. Clin. Exp. Metast. (1996) 14:367-380.
   PubMed Web of Science ®Google Scholar
• SCHMITT M, WILHELM OG, REUNING U et al.: The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis Proteol. (2000) 14:114-132.
   Google Scholar
• BROOKS TD, WANG SW, BRUNNER N, CHARLTON PA: XR5967, a novel modulator of plasminogen activator inhibitor-1 activity, suppresses tumor cell invasion and angiogenesis in vitro. Anticancer Drugs (2004) 15:37-44.
   PubMed Web of Science ®Google Scholar
• MOOK OR, FREDERIKS WM, VAN NOORDEN CJ: The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta (2004) 1705:69-89.
   PubMed Web of Science ®Google Scholar
• EGEBLAD M, WERB Z: New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. (2002) 2:161-174.
   Google Scholar
• CHAU I, RIGG A, CUNNINGHAM D: Matrix metalloproteinase inhibitors – an emphasis on gastrointestinal malignancies. Crit. Rev. Oncol. Hematol. (2003) 45:151-176.
   PubMed Web of Science ®Google Scholar
• BACHMEIER BE, IANCU CM, JOCHUM M, NERLICH AG: Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach. Expert Rev. Anticancer Ther. (2005) 5:149-163.
   PubMed Web of Science ®Google Scholar
• KOS J, LAH TT: Cystatins in human biology. In: Molecular Anatomy and Physiology of Proteins (series). Kopitar Jerala N, Žerovnik E (Eds), NOVA Science Publishers, Inc., NY, USA (2005).
   Google Scholar
• FELBOR U, DREIER L, BRYANT RA, PLOEGH HL, OLSEN BR, MOTHES W: Secreted cathepsin L generates endostatin from collagen XVIII. EMBO J. (2000) 19:1187-1194.
   PubMed Web of Science ®Google Scholar
• O’REILLY MS, HOLMGREN L, SHING Y et al.: Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 79:315-328.
   PubMed Web of Science ®Google Scholar
• PODGORSKI I, LINEBAUGH BE, SAMENI M et al.: Bone microenvironment modulates expression and activity of cathepsin B in prostate cancer. Neoplasia (2005) 7:207-223.
   PubMed Web of Science ®Google Scholar
• MUELLER MM, FUSENIG NE: Friends or foes – bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer (2004) 4:839-849.
   PubMed Web of Science ®Google Scholar
• LITTLEPAGE LE, EGEBLAD M, WERB Z: Coevolution of cancer and stromal cellular responses. Cancer Cell (2005) 7:499-500.
   PubMed Web of Science ®Google Scholar
• VOSSELER S, MIRANCEA N, BOHLEN P, MUELLER MM, FUSENIG NE: Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface hetero-transplants. Cancer Res. (2005) 65:1294-1305.
   PubMed Web of Science ®Google Scholar
• BORGOÑO CA, MICHAEL IP, DIAMANDIS EP: Human tissue kallikreins: physiologic roles and applications in cancer. Mol. Cancer Res. (2004) 2:257-280.
   PubMed Web of Science ®Google Scholar
• KERBEL RS, KAMEN BA: The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer (2004) 4:423-436.
   PubMed Web of Science ®Google Scholar
• GASPARINI G: Metronomic scheduling: the future of chemotherapy? Lancet Oncol. (2001) 2:733-740.
   PubMed Web of Science ®Google Scholar
• HUANG J, SOFFER SZ, KIM ES et al.: Vascular remodeling marks tumors that recur during chronic suppression of angiogenesis. Mol. Cancer Res. (2004) 2:36-42.
   PubMed Web of Science ®Google Scholar
• BORCHERS AH, POWELL MB, FUSENIG NE, BOWDEN GT: Paracrine factor and cell-cell contact-mediated induction of protease and c-ets gene expression in malignant keratinocyte/dermal fibroblast cocultures. Exp. Cell Res. (1994) 213:143-147.
   PubMed Web of Science ®Google Scholar
• SAMENI M, DOSESCU J, MOIN K, SLOANE BF: Functional imaging of proteolysis: stromal and inflammatory cells increase tumor proteolysis. Mol. Imaging (2003) 2:159-175.
   PubMedGoogle Scholar
• TANG Y, KESAVAN P, NAKADA MT, YAN L: Tumor-stroma interaction: positive feedback regulation of extracellular matrix metalloproteinase inducer (EMMPRIN) expression and matrix metalloproteinase-dependent generation of soluble EMMPRIN. Mol. Cancer Res. (2004) 2:73-80.
   PubMed Web of Science ®Google Scholar
• POLLARD JW: Tumour–educated macrophages promote tumour progression and metastasis. Nature Cancer Rev. (2004) 4:71-78.
   PubMed Web of Science ®Google Scholar
• NOEL A, MAILLARD C, ROCKS N et al.: Membrane associated proteases and their inhibitors in tumour angiogenesis. J. Clin. Pathol. (2004) 57:577-584.
   PubMed Web of Science ®Google Scholar
• WEAVER VM, PETERSEN OW, WANG F et al.: Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. (1997) 137:231-245.
   PubMed Web of Science ®Google Scholar
• DVORAK HF: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. (1986) 315:1650-1659.
   PubMed Web of Science ®Google Scholar
• KIRSCHKE H, KEMBHAVI AA, BOHLEY P, BARRETT AJ: Action of rat liver cathepsin L on collagen and other substrates. Biochem. J. (1982) 201:367-372.
   PubMed Web of Science ®Google Scholar
• CONDEELIS JS, WYCKOFF J, SEGALL JE: Imaging of cancer invasion and metastasis using green fluorescent protein. Eur. J. Cancer (2000) 36:1671-1680.
   PubMed Web of Science ®Google Scholar
• HANDSLEY MM, EDWARDS DR: Metalloproteinases and their inhibitors in tumor angiogenesis. Int. J. Cancer (2005) 115:849-860.
   PubMed Web of Science ®Google Scholar
• NISATO RE, HOSSEINI G, SIRRENBERG C et al.: Dissecting the role of matrix metalloproteinases (MMP) and integrin αvβ3 in angiogenesis in vitro: absence of hemopexin C domain bioactivity, but membrane-type 1-MMP and αvβ3 are critical. Cancer Res. (2005) 65:9377-9387.
   PubMed Web of Science ®Google Scholar
• RHEE JS, COUSSENS LM: RECKing MMP function: implications for cancer development. Trends Cell Biol. (2002) 12:209-211.
   PubMed Web of Science ®Google Scholar
• BAUVOIS B: Transmembrane proteases in cell growth and invasion: new contributors to angiogenesis? Oncogene (2004) 23:317-329.
   PubMed Web of Science ®Google Scholar
• PEI D: Matrix metalloproteinases target protease-activated receptors on the tumor cell surface. Cancer Cell (2005) 7:207-208.
   PubMed Web of Science ®Google Scholar
• FOLGUERAS AR, PANDAS AM, SANCHET LM, LOPEZ-OTIN C: Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies. Int. J. Dev. Biol. (2004) 48:411-424.
   PubMed Web of Science ®Google Scholar
• PRIMAKOFF P, MYLES DG: The ADAM gene family: surface proteins with adhesion and protease activity. Trends Genet. (2000) 6:83-87.
   Google Scholar
• FREIJE JM, VALBIN M, PENDAS AM, SANCHEZ LM, PUENTE XS, LOPEZ-OTIN C: Matrix metalloproteinases and tumor progression. Adv. Exp. Biol. (2003) 532:91-107.
   PubMed Web of Science ®Google Scholar
• PORTER S, CLARK IM, KEVORKIAN L, EDWARDS DR: The ADAMTS metalloproteinases. Biochem. J. (2005) 386:15-27.
   PubMed Web of Science ®Google Scholar
• CHANG C, WERB Z: The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol. (2001) 11:S37-S43.
   PubMed Web of Science ®Google Scholar
• LIU XW, TAUBE M, JUNG K-K et al.: Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue–inhibitor of metalloproteinase-1. Cancer Res. (2005) 65:898-906.
   PubMed Web of Science ®Google Scholar
• BLOOMSTON M, SHAFII A, ZERVOS E, ROSEMURGY AS: TIMP-1 antisense gene transfection attenuates the invasive potential of pancreatic cancer cells in vitro and inhibits tumor growth in vivo. Am. J. Surg. (2005) 189:675-679.
   PubMed Web of Science ®Google Scholar
• CHEN EX, SIU LL: Development of molecular targeted anticancer agents: successes, failures and future directions. Curr. Pharm. Des. (2005) 11:265-272.
   PubMed Web of Science ®Google Scholar
• MANNELLO F, TONTI G, PAPA S: Matrix metalloproteinase inhibitors as anticancer therapeutics. Curr. Cancer Drug Targets (2005) 5:285-298.
   PubMed Web of Science ®Google Scholar
• SKILES JW, GONNELLA NC, JENG AY: The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. (2004) 11:2911-2977.
   PubMed Web of Science ®Google Scholar
• TSUCHIYA Y, SAWADA S, YOSHIOKA I et al.: Increased surgical stress promotes tumor metastasis. Surgery (2003) 133:547-555.
   PubMed Web of Science ®Google Scholar
• DOUILLARD JY, PESCHEL C, SHEPHARD F et al.: Randomized Phase II feasibility study of combining the matrix metalloproteinase inhibitor BMS-275291 with paclitaxel plus carboplatin in advanced non-small cell lung cancer. Lung Cancer (2004) 46:361-368.
   PubMed Web of Science ®Google Scholar
• LEIGHL NB, PAZ-ARES L, DOUILLARD JY et al.: Randomized Phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada – Clinical Trials Group Study BR.18. J. Clin. Oncol. (2005) 23:2831-2839.
   PubMed Web of Science ®Google Scholar
• BISSETT D, O’BYRNE KJ, VON PAWEL J et al.: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:842-849.
   PubMed Web of Science ®Google Scholar
• BRAMHALL SR, HALLISSEY MT, WHITING J et al.: Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial. Br. J. Cancer (2002) 86:1864-1870.
   PubMed Web of Science ®Google Scholar
• VIHINEN P, KÄHÄRI VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int. J. Cancer (2002) 99:157-166.
   PubMed Web of Science ®Google Scholar
• MATHIAS A, KOPITZ C, PENNINGTON C et al.: Increase in gelatinase-specificity of matrix-metalloproteinase inhibitors correlates with antimetastatic efficacy in a T-cell lymphoma model. Cancer Res. (2002) 62:5543-5550.
   PubMed Web of Science ®Google Scholar
• SPARANO JA, GRAY R, GIANTONIO B et al.: Evaluating anti-angiogenesis agents in the clinic: the Eastern Co-operative Oncology Group portfolio of clinical trials. Clin. Cancer Res. (2004) 10:1206-1211.
   PubMed Web of Science ®Google Scholar
• KONDRAGANTI S, MOHANAM S, CHINTALA SK et al.: Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res. (2000) 60:6851-6855.
   PubMed Web of Science ®Google Scholar
• MURAOKA RS, DUMOT N, RITTER CA et al.: Blockade of TGF-alpha inhibits mammary tumor cell viability, migration and metastases. J. Clin. Invest. (2002) 109:1551-1559.
   PubMed Web of Science ®Google Scholar
• SIDENIUS N, BLASI F: The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metast. Rev. (2003) 22:205-222.
   PubMed Web of Science ®Google Scholar
• KJØLLER L, ENGELHOLM LH, HOYER-HANSEN M, DANO K, BUGGE TH, BEHRENDT N: uPARAP/endo180 directs lysosomal delivery and degradation of collagen IV. Exp. Cell Res. (2004) 293:106-116.
   PubMed Web of Science ®Google Scholar
• LOOK MP, VAN PUTTEN WL, DUFFY MJ et al.: Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J. Natl. Cancer Inst. (2002) 94:116-128.
   PubMed Web of Science ®Google Scholar
• SCHROHL AS, HOLTEN-ANDERSEN M, SWEEP F et al.: Tumor markers: from laboratory to clinical utility. Mol. Cell Proteomics (2003) 2:378-387.
   PubMed Web of Science ®Google Scholar
• SCHMITT M, HARBECK N, DAIDONE MG et al.: Identification, validation, and clinical implementation of tumor-associated biomarkers to improve therapy concepts, survival, and quality of life of cancer patients: tasks of the Receptor and Biomarker Group of the European Organization for Research and Treatment of Cancer. Int. J. Oncol. (2004) 25:1397-1406.
   PubMed Web of Science ®Google Scholar
• MEIJER-VAN GELDER ME, LOOK MP, PETERS HA et al.: Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res. (2004) 64:4563-4568.
   PubMed Web of Science ®Google Scholar
• GUO Y, HIGAZI AA, ARAKELIAN A et al.: A peptide derived from the nonreceptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J. (2000) 14:1400-1410.
   PubMed Web of Science ®Google Scholar
• RABBANI SA, GLADU J: Urokinase receptor antibody can reduce tumor volume and detect the presence of occult tumor metastases in vivo. Cancer Res. (2002) 62:2390-2397.
   PubMed Web of Science ®Google Scholar
• BU X, KHANKALDYYAN V, GONZALES-GOMEZ I et al.: Species-specific urokinase receptor ligands reduce glioma growth and increase survival primarily by an antiangiogenesis mechanism. Lab. Invest. (2004) 84:667-678.
   PubMed Web of Science ®Google Scholar
• SETYONO-HAN B, STURZEBECHER J, SCHMALIX WA et al.: Suppression of rat breast cancer metastasis and reduction of primary tumour growth by the small synthetic urokinase inhibitor WX-UK1. Thromb. Haemost. (2005) 93:779-786.
   PubMed Web of Science ®Google Scholar
• VALLERA DA, LI C, JIN N, PANOSKALTSIS-MORTARI A, HALL WA: Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J. Natl. Cancer Inst. (2002) 94:597-606.
   PubMed Web of Science ®Google Scholar
• LIU S, BUGGE TH, LEPPLA SH: Targeting of tumor cells by cell surface urokinase plasminogen activator-dependent anthrax toxin. J. Biol. Chem. (2001) 276:17976-17984.
   PubMed Web of Science ®Google Scholar
• VAN DER PLUIJM G, SIJMONS B, VLOEDGRAVEN H et al.: Urokinase-receptor/integrin complexes are functionally involved in adhesion and progression of human breast cancer in vivo. Am. J. Pathol. (2001) 159:971-982.
   PubMed Web of Science ®Google Scholar
• PUTNAM JB, ROYSTON D, CHAMBERS AF et al.: Evaluating the role of serine protease inhibition in the management of tumor micrometastases. Oncology (2003) 17:9-30.
   PubMed Web of Science ®Google Scholar
• SCHULMAN S, LINDMARKER P: Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. N. Engl. J. Med. (2002) 342:1953-1958.
   Web of Science ®Google Scholar
• SAMPSON MT, KAKKAR AK: Coagulation proteases and human cancer. Biochem. Soc. Trans. (2002) 30:201-207.
   PubMed Web of Science ®Google Scholar
• KLERK CP, SMORENBURG SM, OTTEN HM et al.: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J. Clin. Oncol. (2005) 23:2130-2135.
   PubMed Web of Science ®Google Scholar
• SMORENBURG SM, VAN NOORDEN CJ: The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol. Rev. (2001) 53:93-105.
   PubMed Web of Science ®Google Scholar
• CHAPMAN HA, RIESE RJ, SHI GP: Emerging roles for cysteine proteases. Annu. Rev. Physiol. (1997) 59:63-88.
   PubMed Web of Science ®Google Scholar
• VAN NOORDEN CJ, JONGES GN, VAN MARLE J et al.: Heterogenous suppression of experimentally induced colon cancer metastasis in rat liver lobes by inhibition of extracellular cathepsin B. Clin. Exp. Metast. (1998) 16:159-167.
   PubMed Web of Science ®Google Scholar
• GOULET B, BARUCH A, MOON NS et al.: A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Mol. Cell (2004) 14:207-219.
   PubMed Web of Science ®Google Scholar
• CASTINO R, DEMOZ M, ISIDORO C: Destination ‘lysosome’: a target organelle for tumour cell killing? J. Mol. Recognit. (2003) 16:337-348.
   PubMed Web of Science ®Google Scholar
• KROEMER G, JAATTELA M: Lysosomes and autophagy in cell death control. Nat. Rev. Cancer (2005) 5:886-897.
   PubMed Web of Science ®Google Scholar
• BERCHEM G, GLONDU M, GLEIZES M et al.: Cathepsin-D deficient multiple tumour progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene (2002) 21:5951-5955.
   PubMed Web of Science ®Google Scholar
• REINHECKEL T, DEUSSING J, ROTH W, PETERS C: Towards specific functions of lysosomal cysteine peptidases; phenotypes of mice deficient for cathepsin B or cathepsin L. Biol. Chem. (2001) 382:735-741.
   PubMed Web of Science ®Google Scholar
• SELBO PK, HOGSET A, PRASMICKAITE L, BERG K: Photochemical internalisation: a novel drug delivery system. Tumour Biol. (2002) 23:103-112.
   PubMed Web of Science ®Google Scholar
• JEDESZKO C, SLOANE BF: Cysteine cathepsins in human cancer. Biol. Chem. (2004) 385:1017-1027.
   PubMed Web of Science ®Google Scholar
• LAH TT, KOS J: Cysteine proteinases in cancer progression and their clinical relevance for prognosis. Biol. Chem. (1998) 379:125-130.
   PubMed Web of Science ®Google Scholar
• ROCHEFORT H, LIAUDET-COOPMAN E: Cathepsin D in cancer metastasis: a protease and a ligand. APMIS (1999) 107:86-95.
   PubMed Web of Science ®Google Scholar
• JOYCE JA, BARUCH A, CHEHADE K et al.: Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell (2004) 5:443-453.
   PubMed Web of Science ®Google Scholar
• MUNTENER K, ZWICKY R, CSUCS G, BAICI A: The alternative use of exons 2 and 3 in cathepsin B mRNA controls enzyme trafficking and triggers nuclear fragmentation in human cells. Histochem. Cell Biol. (2003) 119:93-101.
   PubMed Web of Science ®Google Scholar
• CALKINS CC, SLOANE BF: Mammalian cysteine peptidase inhibitors: biochemical properties and possible roles in tumor progression. Biol. Chem. (1995) 376:71-80.
   PubMed Web of Science ®Google Scholar
• GLONDU M, LIAUDET-COOPMAN E, DEROCQ D, PLATET N, ROCHEFORT H, GARCIA M: Down-regulation of cathepsin-D expression by antisense gene transfer inhibits tumor growth and experimental lung metastasis of human breast cancer cells. Oncogene (2002) 21:5127-5134.
   PubMed Web of Science ®Google Scholar
• SIVAPARVATHI M, SAWAYA R, CHINTAA SK, GO Y, GOKASLAN ZL, RAO JS: Expression of cathepsin D during the progression of human glioma. Neurosci. Lett. (1996) 208:171-174.
   PubMed Web of Science ®Google Scholar
• HAZEN LG, BLEEKER FE, LAURITZEN B et al.: Comparative localization of cathepsin B protein and activity in colorectal cancer. J. Histochem. Cytochem. (2000) 48:1421-1430.
   PubMed Web of Science ®Google Scholar
• YAN S, SLOANE BF: Molecular regulation of human cathepsin B: Implication in pathologies. Biol. Chem. (2003) 384:845-854.
   PubMed Web of Science ®Google Scholar
• VAN NOORDEN CJ, JONGES TN, MEADE-TOLLIN LC, SMITH RE, KOEHLER A: In vivo inhibition of cysteine proteinases delays the onset of growth of human pancreatic cancer explants. Br. J. Cancer (2000) 82:931-936.
   PubMed Web of Science ®Google Scholar
• BERVAR A, ZAJC I, SEVER N, KATUNUMA N, SLOANE BF, LAH TT: Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol. Chem. (2003) 384:447-455.
   PubMed Web of Science ®Google Scholar
• KRUEGER S, HAECKEL C, BUEHLING F, ROESSNER A: Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res. (1999) 59:6010-6014.
   PubMed Web of Science ®Google Scholar
• GONDI CS, LAKKA SS, DINH DH, OLIVERO WC, GUJRATI M, RAO JS: RNAi-mediated inhibition of cathepsin B and uPAR leads to decreased cell invasion, angiogenesis and tumour growth in gliomas. Oncogene (2004) 23:8486-8496.
   PubMed Web of Science ®Google Scholar
• STROJNIK T, KOS J, ZIDANIK B, GOLOUH R, LAH T: Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res. (1999) 5:559-567.
   PubMed Web of Science ®Google Scholar
• STROJNIK T, KAVALAR R, TRINKAUS M, LAH TT: Cathepsin L in glioma progression: Comparison with cathepsin B. Cancer Detect. Prevent. (2005) 29:448-455.
   PubMedGoogle Scholar
• LEVIČAR N, DEWEY RA, DALEY E et al.: Selective supression of cathepsin L by antisense cDNA impairs human brain tumor cell invasion in vitro and promotes apoptosis. Cancer Gene Ther. (2003) 10:141-151.
   PubMed Web of Science ®Google Scholar
• KRUEGER S, KELLNER U, BUEHLING F, ROESSNER A: Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: Effects on the invasive phenotype. Cancer Gene Ther. (2001) 8:522-528.
   PubMed Web of Science ®Google Scholar
• KIRSCHKE H, EEROLA R, HOPSU-HAVU VK, BROMME D, VUORIO E: Antisense RNA inhibition of cathepsins L expression reduces tumourigenicity of malignant cells. Eur. J. Cancer (2000) 36:787-795.
   PubMed Web of Science ®Google Scholar
• ROUSSELET N, MILLS L, JEAN D, TELLEZ C, BAR-ELI M, FRADE R: Inhibition of tumorigenicity and metastasis of human melanoma cells by anti-cathepsin L single chain variable fragment. Cancer Res. (2004) 64:146-151.
   PubMed Web of Science ®Google Scholar
• ZHENG X, CHOU PM, MIRKIN BL, REBBAA A: Senescence-initiated reversal of drug resistance: specific role of cathepsin L. Cancer Res. (2004) 64:1773-1780.
   PubMed Web of Science ®Google Scholar
• SHI GP, SUKHOVA GK, KUZUYA M et al.: Deficiency of the cysteine protease cathepsin S impairs microvessel growth. Circ. Res. (2003) 92:493-500.
   PubMed Web of Science ®Google Scholar
• URBICH C, HEESCHEN C, AICHER A et al.: Cathepsin L is required for endothelial progenitor cell-induced neovascularization. Nat. Med. (2005) 11:206-212.
   PubMed Web of Science ®Google Scholar
• LAH TT, KALMAN E, NAJJAR D et al.: Cells producing cathepsins D, B and L in human breast carcinoma and their association with prognosis. Hum. Pathol. (2000) 31:149-160.
   PubMed Web of Science ®Google Scholar
• KOS J, SEKIRNIK A, KOPITAR G et al.: Cathepsin S in tumours, regional lymphnodes and sera of patients with lung cancer: relation to prognosis. Br. J. Cancer (2001) 85:1193-1200.
   PubMed Web of Science ®Google Scholar
• SCHUBERT U, ANTON LC, GIBBS J, NORBURY CC, YEWDELL JW, BENNINK JR: Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature (2000) 404:770-774.
   PubMed Web of Science ®Google Scholar
• ADAMS J: The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer (2004) 4:349-360.
   PubMed Web of Science ®Google Scholar
• JEREMIAS I, KUPATT C, BAUMANN B, HERR I, WIRTH T, DEBATIN KM: Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells. Blood (1998) 91:4624-4631.
   PubMed Web of Science ®Google Scholar
• ADAMS J: The development of proteasome inhibitors as anticancer drugs. Cancer Cell (2004) 5:417-421.
   PubMed Web of Science ®Google Scholar
• BOCCADORO M, MORGAN G, CAVENAGH J: Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. (2005) 5:18-26.
   PubMed Web of Science ®Google Scholar
• MITSIADES CS, MITSIADES N, HIDESHIMA T, RICHARDSON PG, ANDERSON KC: Proteasome inhibition as a therapeutic strategy for hematologic malignancies. Expert Rev. Anticancer Ther. (2005) 5:465-476.
   PubMed Web of Science ®Google Scholar
• RAJKUMAR SV, RICHARDSON PG, HIDESHIMA T, ANDERSON KC: Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. (2005) 23:630-639.
   PubMed Web of Science ®Google Scholar
• GEIER E, PFEIFER G, WILM M et al.: A giant protease with potential to substitute for some functions of the proteasome. Science (1999) 283:978-982.
   PubMed Web of Science ®Google Scholar
• RUSSO SM, TEPPER JE, BALDWIN AS JR et al.: Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int. J. Radiat. Oncol. Biol. Phys. (2001) 50:183-193.
   PubMed Web of Science ®Google Scholar
• GLAS R, BOGYO M, MCMASTER JS, GACZYNSKA M, PLOEGH HL: A proteolytic system that compensates for loss of proteasome function. Nature (1998) 392:618-622.
   PubMed Web of Science ®Google Scholar
• REITS E, NEIJSSEN J, HERBERTS C et al.: A major role for TPPII in trimming proteasomal degradation products for MHC class I antigen presentation. Immunity (2004) 20:495-506.
   PubMed Web of Science ®Google Scholar
• STAVROPOULOU V, XIE J, HENDRIKSSON M, TOMKINSON B, IMREH S, MASUCCI MG: Mitotic infidelity and centrosome duplication errors in cells overexpressing tripeptidyl-peptidase II. Cancer Res. (2005) 65:1361-1368.
   PubMed Web of Science ®Google Scholar
• DIAMANDIS EP, YOUSEF GM, OLSSON AY: An update on human and mouse glandular kallikreins. Clin. Biochem. (2004) 37:258-260.
   PubMed Web of Science ®Google Scholar
• MANNELLO F, GAZZANELLI G: Prostate-specific antigen (PSA/hK3): a further player in the field of breast cancer diagnostics? Breast Cancer Res. (2001) 3:238-243.
   PubMed Web of Science ®Google Scholar
• DEFEO-JONES D, BRADY SF, FENG DM et al.: A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Mol. Cancer Ther. (2002) 1:451-459.
   PubMed Web of Science ®Google Scholar
• LATHAM JP, SEARLE PF, MAUTNER V, JAMES ND: Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector. Cancer Res. (2000) 60:334-341.
   PubMed Web of Science ®Google Scholar
• EDER JP, KANTOFF PW, ROPER K et al.: A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. (2000) 6:1632-1638.
   PubMed Web of Science ®Google Scholar
• BARROU B, BENOIT G, OULDKACI M et al.: Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA. Cancer Immunol. Immunother. (2004) 53:453-460.
   PubMed Web of Science ®Google Scholar
• PERRIN BJ, HUTTENLOCHER A: Calpain. Int. J. Biochem. Cell Biol. (2002) 34:722-725.
   PubMed Web of Science ®Google Scholar
• CARRAGHER NO, FRAME MC: Calpain: a role in cell transformation and migration. Int. J. Biochem. Cell Biol. (2002) 34:1539-1543.
   PubMed Web of Science ®Google Scholar
• GLADING A, CHANG P, LAUFFENBURGER DA, WELLS A: Epidermal growth factor receptor activation of calpain is required for fibroblast motility and occurs via an ERK/MAP kinase signaling pathway. J. Biol. Chem. (2000) 275:2390-2398.
   PubMed Web of Science ®Google Scholar
• CARRAGHER NO, WESTHOFF MA, RILEY D et al.: v-Src-induced modulation of the calpain-calpastatin proteolytic system regulates transformation. Mol. Cell Biol. (2002) 22:257-269.
   PubMed Web of Science ®Google Scholar
• CARRAGHER NO, FONSECA BD, FRAME MC: Calpain activity is generally elevated during transformation but has oncogene-specific biological functions. Neoplasia (2004) 6:53-73.
   PubMed Web of Science ®Google Scholar
• MAMOUNE A, LUO JH, LAUFFENBURGER DA, WELLS A: Calpain-2 as a target for limiting prostate cancer invasion. Cancer Res. (2003) 63:4632-4640.
   PubMed Web of Science ®Google Scholar
• JEE CD, LEE HS, BAE SI et al.: Loss of caspase1 gene expression in human gastric carcinomas and cell lines. Int. J. Oncol. (2005) 26:1265-1271.
   PubMed Web of Science ®Google Scholar
• NIKITINA EY, DESAI SA, ZHAO X et al.: Versatile prostate cancer treatment with inducible caspase and interleukin-12. Cancer Res. (2005) 65:4309-4319.
   PubMed Web of Science ®Google Scholar
• OVERALL CM, TAM EM, KAPPELHOFF R et al.: Protease degradomics: mass spectrometry discovery of protease substrates and the CLIP-CHIP, a dedicated DNA microarray of all human proteases and inhibitors. Biol. Chem. (2004) 385:493-504.
   PubMed Web of Science ®Google Scholar
• FERRARI M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer (2005) 5:161-171.
   PubMed Web of Science ®Google Scholar
• YANAMANDRA N, KONDRAGANTI S, GONDI CS et al.: Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int. J. Cancer (2005) 115:998-1005.
   PubMed Web of Science ®Google Scholar
• HARTL I, SCHNEIDER RM, SUN Y et al.: Library-based selection of retroviruses selectively spreading through matrix metalloprotease-positive cells. Gene Ther. (2005) 12:918-926.
   PubMed Web of Science ®Google Scholar
• READ TA, SORENSEN DR, MAHESPARAN R et al.: Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat. Biotechnol. (2001) 19:29-34.
   PubMed Web of Science ®Google Scholar
• YOON WH, JUNG YJ, KIM TD et al.: Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin. Cancer Res. (2004) 10:4517-4526.
   PubMed Web of Science ®Google Scholar
• OVERALL CM, LÓPEZ-OTÍN C: Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer (2002) 2:657-672.
   PubMed Web of Science ®Google Scholar
• GUO Y, MAZAR AP, LEBRUN JJ, RABBANI SA: An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer. Cancer Res. (2002) 62:4678-4684.
   PubMed Web of Science ®Google Scholar
• CHAMBERS AF, MACDONALD IC, SCHMIDT EE, MORRIS VL, GROOM AC: Preclinical assessment of anti-cancer therapeutic strategies using in vivo videomicroscopy. Cancer Metast. Rev. (1998) 17:263-269.
   PubMed Web of Science ®Google Scholar
• MOOK OR, VAN MARLE J, VREELING-SINDELAROVA H, JONGES R, FREDERIKS WM, VAN NOORDEN CJ: Visualization of early events in tumor formation of eGFP-transfected rat colon cancer cells in liver. Hepatology (2003) 38:295-304.
   PubMed Web of Science ®Google Scholar